1.Alternative Name:SLC39A6/ZIP6
2.Target:LIV-1
3.Source:Human IL-18R alpha was expressed from HEK293 with human IgG1 FC at the C-terminal
4.Sequence:Phe29-Trp325
5.Protein structure:Q13478hFC
6.Molecular Characterization:The protein has a calculated MW of 61kDa.The reducing (R) heterodimer protein migrates as 70-100 kDa due to glycosylation
7.Purity:SDS-PAGE>90%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10.Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.

11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 90%.

12.ELISA

When Recombinant Human LIV-1（29-325）/hFC Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Anti-Human LIV-1 / SLC39A6(ladiratuzumab) that produces 50% of the optimal binding response is approximately 0.3 ug/ml.
Note
For research use only .